I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -1.1, beating the estimate of USD -1.2394.
EBIT: As of FY2026 Q2, the actual value is USD -132.57 M.
Financial Performance for Q2 and Six Months Ended June 30, 2026
Net Loss
For the three months ended June 30, 2026, Viking Therapeutics, Inc. reported a net loss of -$128.0 million, compared to -$65.6 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was -$286.3 million, compared to -$111.2 million for the same period in 2025.
Research and Development Expenses
Research and development expenses for the three months ended June 30, 2026, were $115.8 million, an increase from $60.2 million for the same period in 2025, primarily due to increased expenses in clinical studies, salaries, benefits, stock-based compensation, and third-party consultants. For the six months ended June 30, 2026, these expenses were $265.9 million, up from $101.5 million for the same period in 2025, driven by increased expenses in clinical studies, salaries, benefits, third-party consultants, and stock-based compensation.
General and Administrative Expenses
General and administrative expenses for the three months ended June 30, 2026, were $16.9 million, an increase from $14.4 million for the same period in 2025, mainly due to increased expenses for third-party consultants, legal and patent services, salaries, and benefits. For the six months ended June 30, 2026, these expenses totaled $30.8 million, an increase from $28.5 million for the same period in 2025, primarily due to increased expenses for third-party consultants, salaries, and benefits.
Total Operating Expenses
Total operating expenses for the three months ended June 30, 2026, were $132.6 million, compared to $74.6 million for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $296.7 million, compared to $130.0 million for the same period in 2025.
Loss from Operations
Loss from operations for the three months ended June 30, 2026, was -$132.6 million, compared to -$74.6 million for the same period in 2025. For the six months ended June 30, 2026, the loss from operations was -$296.7 million, compared to -$130.0 million for the same period in 2025.
Interest Income, Net
Net interest income for the three months ended June 30, 2026, was $4.5 million, compared to $9.0 million for the same period in 2025. For the six months ended June 30, 2026, net interest income was $10.3 million, compared to $18.9 million for the same period in 2025.
Realized Gain on Investments
A realized gain on investments for the three months ended June 30, 2026, was $0.03 million, compared to $0.004 million for the same period in 2025. For the six months ended June 30, 2026, the realized gain on investments was $0.03 million, compared to $0.004 million for the same period in 2025.
Total Other Income, Net
Total other income, net, for the three months ended June 30, 2026, was $4.6 million, compared to $9.0 million for the same period in 2025. For the six months ended June 30, 2026, total other income, net, was $10.4 million, compared to $18.9 million for the same period in 2025.
Comprehensive Loss
Comprehensive loss for the three months ended June 30, 2026, was -$128.3 million, compared to -$65.5 million for the same period in 2025. For the six months ended June 30, 2026, comprehensive loss was -$287.9 million, compared to -$110.6 million for the same period in 2025.
Balance Sheet Highlights as of June 30, 2026
Cash, Cash Equivalents, and Short-term Investments
Viking Therapeutics, Inc. held $502 million in cash, cash equivalents, and short-term investments as of June 30, 2026, a decrease from $706 million as of December 31, 2025.
Total Assets
Total assets were $521.9 million as of June 30, 2026, compared to $715.7 million as of December 31, 2025.
Total Liabilities
Total liabilities increased to $113.6 million as of June 30, 2026, from $76.7 million as of December 31, 2025.
Total Stockholders’ Equity
Total stockholders’ equity was $408.3 million as of June 30, 2026, compared to $639.1 million as of December 31, 2025.
Operational Metrics and Corporate Updates
The Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in obesity are fully enrolled and progressing as planned. Viking Therapeutics, Inc. expanded its obesity portfolio by initiating a Phase 1 clinical trial of VK3019, an investigational amylin receptor agonist. Hubert Chen, M.D., was appointed as chief medical officer, and Dorothy Gemmell was appointed to the board of directors.
Outlook and Guidance
Viking Therapeutics, Inc. expects to initiate the Oral Phase 3 VK2735 Trial in the fourth quarter of 2026, and results from the VK2735 Maintenance Dosing Study are anticipated in the third quarter of 2026. The company is advancing VK3019 into clinical development, believing it may offer another important potential treatment option for patients with obesity and overweight.